• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927).
  
• Mutation; HGNC; 7133; KMT2D; Simple; p.Glu341Gln (c.1021G>C); Zygosity=Heterozygous (PubMed=31541927).
  
• Mutation; HGNC; 7133; KMT2D; Simple; p.Leu1935Val (c.5803C>G); Zygosity=Heterozygous (PubMed=31541927).
  
• Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1679Ter (c.5035G>T); Zygosity=Homozygous (PubMed=31541927).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (PubMed=18006756; PubMed=23613873; PubMed=31541927).
  
• Mutation; HGNC; 11998; TP53; Simple; c.993+1G>T (IVS9+1G>T); ClinVar=VCV000634766; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=18006756; PubMed=23613873; PubMed=31541927).
  

PubMed=1958593; DOI=10.1002/gcc.2870030406
Bradford C.R., Kimmel K.A., Van Dyke D.L., Worsham M.J., Tilley B.J., Burk D., del Rosario F., Lutz S., Tooley R., Hayashida D.J.S., Carey T.E.
11p deletions and breakpoints in squamous cell carcinoma: association with altered reactivity with the UM-E7 antibody.
Genes Chromosomes Cancer 3:272-282(1991)

DOI=10.1016/B978-0-12-333530-2.50007-1
Carey T.E.
Head and neck tumor cell lines.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York; USA (1994)

PubMed=9139877; DOI=10.1002/(SICI)1097-0215(19970502)71:3<410::AID-IJC18>3.0.CO;2-J
Welters M.J.P., Fichtinger-Schepman A.M.J., Baan R.A., Hermsen M.A.J.A., van der Vijgh W.J.F., Cloos J., Braakhuis B.J.M.
Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines.
Int. J. Cancer 71:410-415(1997)

PubMed=15287027; DOI=10.1002/gcc.20066
Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y., Grenman R., Fisher S.G., Carey T.E.
Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer.
Genes Chromosomes Cancer 41:145-154(2004)

PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=18006756; DOI=10.1158/1078-0432.CCR-07-1591
Friedman J., Nottingham L.K., Duggal P., Pernas F.G., Yan B., Yang X.-P., Chen Z., Van Waes C.
Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
Clin. Cancer Res. 13:6568-6578(2007)

PubMed=19760794; DOI=10.1002/hed.21198; PMCID=PMC3292176
Brenner J.C., Graham M.P., Kumar B., Saunders L.M., Kupfer R., Lyons R.H., Bradford C.R., Carey T.E.
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines.
Head Neck 32:417-426(2010)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=23613873; DOI=10.1371/journal.pone.0061555; PMCID=PMC3629194
Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A., Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
PLoS ONE 8:E61555-E61555(2013)

PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528
Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B., Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A., Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.
Defects in the Fanconi anemia pathway and chromatid cohesion in head and neck cancer.
Cancer Res. 75:3543-3553(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29156801; DOI=10.18632/oncotarget.21174; PMCID=PMC5689691
Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y., Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.
Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.
Oncotarget 8:86369-86383(2017)

PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004; PMCID=PMC7372097
van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I., Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.
Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
Oral Oncol. 98:53-61(2019)